HomeInsightsStock Comparison

Cipla Ltd vs Torrent Pharmaceuticals Ltd Stock Comparison

Cipla Ltd vs Torrent Pharmaceuticals Ltd Stock Comparison

Last Updated on: Apr 27, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1525 as of 25 Apr 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Torrent Pharmaceuticals Ltd changed from 32.6 on March 2020 to 53.2 on March 2024 . This represents a CAGR of 10.29% over 5 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Torrent Pharmaceuticals Ltd changed from ₹ 33361 crore on March 2020 to ₹ 88030 crore on March 2024 . This represents a CAGR of 21.42% over 5 years.
  • The revenue of Cipla Ltd for the Dec '24 is ₹ 7294 crore as compare to the Sep '24 revenue of ₹ 7241 crore. This represent the growth of 0.73% The revenue of Torrent Pharmaceuticals Ltd for the Dec '24 is ₹ 2842 crore as compare to the Sep '24 revenue of ₹ 2873 crore. This represent the decline of -1.08%.
  • The ebitda of Cipla Ltd for the Dec '24 is ₹ 2210 crore as compare to the Sep '24 ebitda of ₹ 2076 crore. This represent the growth of 6.47% The ebitda of Torrent Pharmaceuticals Ltd for the Dec '24 is ₹ 947 crore as compare to the Sep '24 ebitda of ₹ 923 crore. This represent the growth of 2.6%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1583 crore over 7 quarters. This represents a CAGR of 30.30% The net profit of Torrent Pharmaceuticals Ltd changed from ₹ 378 crore to ₹ 503 crore over 7 quarters. This represents a CAGR of 17.73% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Torrent Pharmaceuticals Ltd changed from 57.71 % on March 2020 to 69.83 % on March 2024 . This represents a CAGR of 3.89% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Ltd is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd.

About Torrent Pharmaceuticals Ltd

  • Torrent Pharmaceuticals Limited, the flagship Company of the Torrent Group, is one of the leading pharmaceutical companies having presence in Indian and global markets.
  • The Company is a dominant player in the therapeutic areas of Cardiovascular (CV), Central Nervous System (CNS), Vitamins and Nutrients (VMN), Gastro-Intestinal (GI) and Anti-Diabetes (AD) therapies in India.
  • It has a strong international presence across more than 40 countries with operations in regulated and emerging markets, such as the US, Europe, Brazil and Rest of the World. The Company operates through its wholly-owned subsidiaries spread across 12 countries with major setups in the US, Germany and Brazil.
  • Apart from this, it has a modern and well-equipped state-of-the-art R&D Centre at Bhat near Ahmedabad, built with an investment of US $ 40 million.

Cipla Ltd News Hub

News

Cipla's Goa API facility receives VAI status from USFDA

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection o...

Read more

21 Apr 2025 11:32

News

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

17 Apr 2025 16:12

News

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Cipla has received final approval from the United States Food and Drug Administration (USF...

Read more

11 Apr 2025 09:27

News

Cipla jumps on receiving approval from USFDA for protein-bound Paclitaxel

Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for...

Read more

11 Apr 2025 10:12

News

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025. Powered...

Read more

08 Apr 2025 09:40

News

USFDA classifies cGMP inspection of Cipla's Virgonagar facility as VAI

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the com...

Read more

08 Feb 2025 11:16

Torrent Pharmaceuticals Ltd News Hub

News

Torrent Pharmaceuticals announces resignation of ED (Strategic Planning)

Torrent Pharmaceuticals announced that Pranav Mehta, Executive Director (Strategic Plannin...

Read more

27 Feb 2025 18:47

News

Torrent Pharmaceuticals Ltd rises for third consecutive session

Torrent Pharmaceuticals Ltd gained for a third straight session today. The stock is quotin...

Read more

07 Feb 2025 13:05

News

Torrent Pharmaceuticals Ltd slips for fifth straight session

Torrent Pharmaceuticals Ltd is down for a fifth straight session today. The stock is quoti...

Read more

04 Feb 2025 13:35

News

Torrent Pharma gains after Q3 PAT rises 14% YoY to Rs 503 cr

Revenue from operations grew 2.6% year on year (YoY) to Rs 2,762 crore in the quarter ende...

Read more

27 Jan 2025 14:33

News

Board of Torrent Pharmaceuticals recommends interim dividend

Torrent Pharmaceuticals announced that the Board of Directors of the Company at its meetin...

Read more

24 Jan 2025 17:25

News

Torrent Pharmaceuticals to declare Quarterly Result

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24...

Read more

15 Jan 2025 10:12

SWOT Analysis Of Torrent Pharmaceuticals Ltd

Strength

4

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Torrent Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Torrent Pharmaceuticals Ltd

Which company has a larger market capitalization, Cipla Ltd or Torrent Pharmaceuticals Ltd?

Market cap of Cipla Ltd is 123,201 Cr while Market cap of Torrent Pharmaceuticals Ltd is 109,514 Cr

What are the key factors driving the stock performance of Cipla Ltd and Torrent Pharmaceuticals Ltd?

The stock performance of Cipla Ltd and Torrent Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Torrent Pharmaceuticals Ltd?

As of April 27, 2025, the Cipla Ltd stock price is INR ₹1525.5. On the other hand, Torrent Pharmaceuticals Ltd stock price is INR ₹3235.95.

How do dividend payouts of Cipla Ltd and Torrent Pharmaceuticals Ltd compare?

To compare the dividend payouts of Cipla Ltd and Torrent Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions